The prognosis and adjuvant chemotherapy in KRAS mutation patients with stage I lung adenocarcinoma
Background: Adjuvant chemotherapy (ACT) remains the current first-line systemic treatment option for patients with KRAS-mutated lung adenocarcinoma (LUAD), but the response is not effective. The prognosis of ACT in patients with KRAS mutations in stage I LUAD has not yet been effectively explored. M...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-12-01
|
| Series: | Clinical Surgical Oncology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2773160X24000370 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|